Table III.
Clinical features between the high and low LMR groups.
| LMR | |||
|---|---|---|---|
| Characteristics | ≤2.22 (n=86) | >2.22 (n=88) | P-value |
| Age, years | 54.4±4.51 | 56.8±13.2 | 0.217 |
| Sex | |||
| Male | 76 | 81 | 0.415 |
| Female | 10 | 7 | |
| Leukocytes, ×109 cells/l | 8.0±4.3 | 5.7±2.1 | 0.000 |
| Neutrophils, ×109 cells/l | 6.1±3.5 | 3.7±1.8 | 0.000 |
| Monocytes, ×109 cells/l | 0.8±0.6 | 0.4±0.2 | 0.000 |
| Lymphocytes, ×109 cells/l | 1.1±0.6 | 1.4±0.5 | 0.000 |
| Platelets, ×109 cells/l | 164.1±109.4 | 148.7±95.0 | 0.584 |
| Hemoglobin, g/l | 112.3±21.7 | 118.3±21.7 | 0.068 |
| AST, U/l | 266.4±323.9 | 164.6±200.8 | 0.002 |
| Total bilirubin, µmol/l | 105.2±136.7 | 72.6±108.0 | 0.002 |
| Albumin, g/l | 32.0±6.3 | 33.9±6.1 | 0.045 |
| ALP, U/l | 212.7±144.2 | 148.3±76.1 | 0.006 |
| BUN, mmol/l | 6.8±4.2 | 6.1±3.2 | 0.546 |
| Creatinine, µmol/l | 75.2±30.2 | 76.4±27.6 | 0.137 |
| AFU, U/l | 30.3±17.4 | 29.7±18.5 | 0.758 |
| GGT, U/l | 292.9±268.4 | 215.3±179.7 | 0.091 |
| Prothrombin time, sec | 70.6±18.1 | 75.4±19.5 | 0.088 |
| INR | 1.3±0.3 | 1.3±0.3 | 0.125 |
| Lymph node metastasis | |||
| Absent | 54 | 67 | 0.056 |
| Present | 32 | 21 | |
| Distant metastasis | |||
| Absent | 60 | 78 | 0.002 |
| Present | 36 | 0 | |
| PVTT | |||
| Absent | 18 | 30 | 0.052 |
| Present | 68 | 58 | |
| Tumor number | |||
| ≤3 | 34 | 43 | 0.215 |
| >3 | 52 | 45 | |
| Tumor size, cm | |||
| <2 | 12 | 28 | 0.005 |
| ≥2 | 74 | 60 | |
| Ascites | |||
| Absent | 15 | 44 | 0.000 |
| Present | 71 | 44 | |
| 3-Month survival rate, % | 25.6 (22/86) | 55.7 (49/88) | 0.000 |
| 6-Month survival rate, % | 14.0 (12/86) | 37.5 (33/88) | 0.000 |
LMR, leukocyte-to-monocyte ratio; AST, aspartate transaminase; ALP, alkaline phosphatase; BUN, blood urea nitrogen; AFU, α-L-fucosidase; GGT, γ-glutamyl transpeptidase; PVTT, portal vein tumor thrombus; INR, international normalized ratio.